BACKGROUND: Fibroblast growth factor 19 (FGF19)-mediated activation of mitogen-activated protein kinase and the β-catenin pathway may be involved in the development and progression of hepatocellular carcinoma. This study aimed to elucidate the prognostic significance of FGF19 protein expression in hepatocellular carcinoma patients. METHODS: By immunohistochemistry, we investigated the expression of FGF19 protein in tumor tissue from 281 hepatocellular carcinoma patients who underwent curative hepatectomy. Univariate and multivariate analyses were performed to evaluate its predictive value for tumor recurrence and survival of patients. The median follow-up period was 75.6 months. RESULTS: FGF19 protein expression was observed in 135 (48.0 %) of the 281 hepatocellular carcinomas. FGF19 expression was significantly associated with larger tumor size (P < 0.001), and higher BCLC stage (P = 0.001). FGF19 expression was correlated with the early recurrence (P < 0.001), but not with the late recurrence (P = 0.582). FGF19 expression (P = 0.002), viral etiology (P = 0.028), and intrahepatic metastasis (P < 0.001) were independent predictors of early recurrence. Multivariate analyses of survival revealed that FGF19 expression (P < 0.001), intrahepatic metastasis (P < 0.001), and liver cirrhosis (P = 0.019) were independent predictors of shorter disease-free survival. FGF19 expression (P = 0.005), larger tumor size (P = 0.038), major portal vein invasion (P = 0.048), intrahepatic metastasis (P < 0.001), lower albumin level (P = 0.024), and liver cirrhosis (P = 0.031) were independent predictors of shorter disease-specific survival. CONCLUSIONS: FGF19 protein expression might be an effective predictor of early recurrence and a marker for poor prognosis of hepatocellular carcinoma after curative hepatectomy, indicating that FGF19 might be a potential preventive target in hepatocellular carcinoma patients.
BACKGROUND:Fibroblast growth factor 19 (FGF19)-mediated activation of mitogen-activated protein kinase and the β-catenin pathway may be involved in the development and progression of hepatocellular carcinoma. This study aimed to elucidate the prognostic significance of FGF19 protein expression in hepatocellular carcinomapatients. METHODS: By immunohistochemistry, we investigated the expression of FGF19 protein in tumor tissue from 281 hepatocellular carcinomapatients who underwent curative hepatectomy. Univariate and multivariate analyses were performed to evaluate its predictive value for tumor recurrence and survival of patients. The median follow-up period was 75.6 months. RESULTS:FGF19 protein expression was observed in 135 (48.0 %) of the 281 hepatocellular carcinomas. FGF19 expression was significantly associated with larger tumor size (P < 0.001), and higher BCLC stage (P = 0.001). FGF19 expression was correlated with the early recurrence (P < 0.001), but not with the late recurrence (P = 0.582). FGF19 expression (P = 0.002), viral etiology (P = 0.028), and intrahepatic metastasis (P < 0.001) were independent predictors of early recurrence. Multivariate analyses of survival revealed that FGF19 expression (P < 0.001), intrahepatic metastasis (P < 0.001), and liver cirrhosis (P = 0.019) were independent predictors of shorter disease-free survival. FGF19 expression (P = 0.005), larger tumor size (P = 0.038), major portal vein invasion (P = 0.048), intrahepatic metastasis (P < 0.001), lower albumin level (P = 0.024), and liver cirrhosis (P = 0.031) were independent predictors of shorter disease-specific survival. CONCLUSIONS:FGF19 protein expression might be an effective predictor of early recurrence and a marker for poor prognosis of hepatocellular carcinoma after curative hepatectomy, indicating that FGF19 might be a potential preventive target in hepatocellular carcinomapatients.
Authors: Hiroshi Kurosu; Mihwa Choi; Yasushi Ogawa; Addie S Dickson; Regina Goetz; Anna V Eliseenkova; Moosa Mohammadi; Kevin P Rosenblatt; Steven A Kliewer; Makoto Kuro-o Journal: J Biol Chem Date: 2007-07-10 Impact factor: 5.157
Authors: Eric T Sawey; Maia Chanrion; Chunlin Cai; Guanming Wu; Jianping Zhang; Lars Zender; Alice Zhao; Ronald W Busuttil; Herman Yee; Lincoln Stein; Dorothy M French; Richard S Finn; Scott W Lowe; Scott Powers Journal: Cancer Cell Date: 2011-03-08 Impact factor: 31.743
Authors: Katrina Nicholes; Susan Guillet; Elizabeth Tomlinson; Kenneth Hillan; Barbara Wright; Gretchen D Frantz; Thinh A Pham; Lisa Dillard-Telm; Siao Ping Tsai; Jean-Philippe Stephan; Jeremy Stinson; Timothy Stewart; Dorothy M French Journal: Am J Pathol Date: 2002-06 Impact factor: 4.307
Authors: Yujin Hoshida; Augusto Villanueva; Masahiro Kobayashi; Judit Peix; Derek Y Chiang; Amy Camargo; Supriya Gupta; Jamie Moore; Matthew J Wrobel; Jim Lerner; Michael Reich; Jennifer A Chan; Jonathan N Glickman; Kenji Ikeda; Masaji Hashimoto; Goro Watanabe; Maria G Daidone; Sasan Roayaie; Myron Schwartz; Swan Thung; Helga B Salvesen; Stacey Gabriel; Vincenzo Mazzaferro; Jordi Bruix; Scott L Friedman; Hiromitsu Kumada; Josep M Llovet; Todd R Golub Journal: N Engl J Med Date: 2008-10-15 Impact factor: 91.245
Authors: Dorothy M French; Benjamin C Lin; Manping Wang; Camellia Adams; Theresa Shek; Kathy Hötzel; Brad Bolon; Ronald Ferrando; Craig Blackmore; Kurt Schroeder; Luis A Rodriguez; Maria Hristopoulos; Rayna Venook; Avi Ashkenazi; Luc R Desnoyers Journal: PLoS One Date: 2012-05-15 Impact factor: 3.240
Authors: Quan Zhang; Yan Li; Tingting Liang; Xuemian Lu; Xingkai Liu; Chi Zhang; Xin Jiang; Robert C Martin; Mingliang Cheng; Lu Cai Journal: Am J Cancer Res Date: 2015-04-15 Impact factor: 6.166
Authors: Cheng Mo; Zhang Zhang; Christopher P Guise; Xueqiang Li; Jinfeng Luo; Zhengchao Tu; Yong Xu; Adam V Patterson; Jeff B Smaill; Xiaomei Ren; Xiaoyun Lu; Ke Ding Journal: ACS Med Chem Lett Date: 2017-03-31 Impact factor: 4.345
Authors: Xiaojing Lin; Yuliana Yosaatmadja; Maria Kalyukina; Martin J Middleditch; Zhen Zhang; Xiaoyun Lu; Ke Ding; Adam V Patterson; Jeff B Smaill; Christopher J Squire Journal: ACS Med Chem Lett Date: 2019-07-03 Impact factor: 4.345